On Wednesday, Shares of Halliburton Company (NYSE:HAL), lost -3.50% to $41.07, as U.S. oil futures settled at a more than three month low Wednesday, plagued by persistent worries over strong crude production as traders assessed the latest weekly petroleum-supply update and the impact of Iran’s nuclear deal.
On the New York Mercantile Exchange, August West Texas Intermediate crude fell $1.63, or 3.1%, to settle at $51.41 a barrel. Prices marked their lowest settlement since April 9, based on the most-active contracts. Market Watch Reports.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Shares of Bristol-Myers Squibb Company (NYSE:BMY), declined -1.11% to $69.28, during its last trading session, hitting its highest level.
The Medical University of South Carolina and Bristol-Myers Squibb Company (BMY) declared that they have entered into a translational research partnership focused on fibrotic diseases, counting scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. The agreement comprises studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.
“Bristol-Myers Squibb’s partnership with MUSC further strengthens and advances our Discovery research efforts in fibrotic diseases, a planned area of focus for the company,” said Carl Decicco, Ph.D., Head of Discovery, R&D, Bristol-Myers Squibb. “MUSC brings substantial expertise in translational research and drug discovery related to fibrotic diseases counting access to patient derived disease tissue samples that will assist us accelerate the application of scientific knowledge to potential new treatment approaches for patients.”
“This is an exciting opportunity with the potential to make a noteworthy impact in fibrotic diseases and in patients’ lives with these debilitating diseases,” said Karen Lackey, MUSC Center for Therapeutic Discovery and Development executive director and pharmacy associate professor. “Our aim with translational research is to shorten the timeline in getting patients the medications and treatments they need. We have unparalleled expertise in fibrosis research at MUSC, and this partnership with a leader like Bristol-Myers Squibb in discovery and development of medications is going to take that foundational work to the next level.”
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Finally, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), ended its last trade with -1.04% loss, and closed at $11.41.
Ironwood Pharmaceuticals, declared it will host its second quarter 2015 investor update conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 5, 2015. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 83522769.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
